Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
117.46
+0.06 (+0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
71
72
Next >
The 3 Best Healthcare Stocks to Buy in August
August 09, 2023
Healthcare is always the answer in the face of volatility. Here are the three best healthcare stocks to buy in the sector.
Via
InvestorPlace
Mirati Rockets 26% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit
August 09, 2023
The company announced updates in cancer, a quarterly beat, a $300 million deal and its CEO departure.
Via
Investor's Business Daily
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
August 09, 2023
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the...
Via
Benzinga
Merck & Co Unusual Options Activity
August 08, 2023
Via
Benzinga
Merck Is Driving Ginkgo Bioworks Stock Higher Monday: What's Going On?
August 07, 2023
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher Monday after the company announced a collaboration with Merck & Company Inc (NYSE: MRK) focused on
Via
Benzinga
Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling
August 07, 2023
The Nasdaq 100 closed lower on Thursday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
This Is What Whales Are Betting On Merck & Co
August 04, 2023
Via
Benzinga
Peering Into Merck & Co's Recent Short Interest
August 03, 2023
Via
Benzinga
Expert Ratings for Merck & Co
August 02, 2023
Via
Benzinga
Is It Time to Buy the Dow Jones' 3 Worst-Performing July Stocks?
August 03, 2023
These three Dow stocks had a tough go of it in July; is the pain over, or are investors in for more hurt in the months ahead?
Via
The Motley Fool
Fear & Greed Index Moves To 'Greed' Zone After S&P 500 Settles Lower
August 02, 2023
U.S. stocks closed mixed on Tuesday, as investors digested recent earnings reports and a fresh batch of economic data.
Via
Benzinga
Exact Sciences, A Cathie Wood Darling, Just Reported A Sixth Big Sales Quarter
August 01, 2023
The company is a leader in using diagnostics to screen for early cancer cases.
Via
Investor's Business Daily
Merck (MRK) Q2 2023 Earnings Call Transcript
August 01, 2023
MRK earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Mixed Brew: Pfizer, Merck Earnings Head Opposite Ways, But Uber And Caterpillar Slug Line Drives
August 01, 2023
(Tuesday market open) The new month starts with stocks tinted red, but this week’s main events are just getting underway. A rise in Treasury yields might have investors nervous early Tuesday as the...
Via
Benzinga
Merck & Co's Earnings Outlook
July 31, 2023
Via
Benzinga
The 2 Dow Stocks Everyone's Watching Tuesday Morning
August 01, 2023
Find out the latest on these blue chip companies.
Via
The Motley Fool
Merck Swings Into Q2 Loss On Prometheus Biosciences Acquisition Charge, But Raises FY23 Revenue Outlook
August 01, 2023
Merck & Co Inc's (NYSE: MRK) Q2 sales reached $15.04 billion, up 3% Y/Y, beating the consensus of $14.39 billion.
Via
Benzinga
Nasdaq, S&P 500 Futures Pullback After Strong July; Why This Analyst Recommends Staying Fully Invested
August 01, 2023
Via
Benzinga
Merck Outplays The Covid Decline, But Prometheus Buyout Weighs On Profits
August 01, 2023
Merck beat sales expectations on Tuesday, though reported losses due to its Prometheus takeover.
Via
Investor's Business Daily
Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda
July 31, 2023
Pharmaceutical company Merck & Company (NYSE: MRK) reports second quarter financial results before market open Tuesday.
Via
Benzinga
Earnings Extravaganza: Another One-Third Of S&P 500 Companies Report This Week, Including Amazon, Apple
July 31, 2023
(Monday market open) It’s “tech week” on Wall Street. No, wait, it’s “pharma week.” Or is it “employment week?” How about all three?
Via
Benzinga
3 Pharma Stocks to Buy for Their Promising Progress
July 31, 2023
Explore the top promising pharma stocks, leading the proverbial marathon towards transformative healthcare.
Via
InvestorPlace
7 Dow Stocks to Buy as Recession Fears Roll Back
July 30, 2023
These Dow stocks to buy are stable and look stronger as soft landing perspectives look more and more possible this year.
Via
InvestorPlace
The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets
July 28, 2023
Via
Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.
Via
Benzinga
Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine
July 27, 2023
Merck & Co Inc (NYSE: MRK) announced topline results from two Phase 3 trials evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve
Via
Benzinga
Jim Cramer Recommends Holding This Health Care Stock: 'Re-Inventing Itself, Doing A Terrific Job'
July 27, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Tri Pointe Homes, Inc. (NYSE: TPH) is "still good.
Via
Benzinga
Individualized Cancer Treatment: Merck/Moderna's Personalized Skin Cancer Therapy Enters Late-Stage Of Development
July 26, 2023
Merck & Co Inc (NYSE: MRK) and Moderna Inc (NASDAQ: MRNA) initiated a pivotal Phase 3 randomized V940-001 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT),...
Via
Benzinga
Moderna On Cathie Wood's Radar Ahead Of Q2 Results: Ark Boosts Stake In COVID-19 Vaccine Maker By $12M This Week
July 26, 2023
Cathie Wood's Ark Invest bought over $12 million worth of Moderna shares as the biopharma expands its pipeline beyond COVID-19.
Via
Benzinga
Russia Is Seizing European Company Assets — What US Businesses Are Still At Risk?
July 24, 2023
Via
Benzinga
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.